Oriflame’s latest scientific findings reveal that its patented bioactivating technology, Oripeptide-3, significantly supports five key biological drivers of skin ageing, marking a notable advancement in the brand’s NovAge+ range. Developed over nearly 20 years, Oripeptide-3 works with the skin’s natural biology to enhance DNA protection, protein quality, cellular renewal, energy for repair, and overall skin function, supporting healthier, resilient, and youthful-looking skin.
“Longevity is the next frontier in beauty, and our research at the molecular and cellular level positions Oriflame at the forefront of this transformation,” said Dr. LeneVisdal-Johnsen, Director, Scientific Research and Innovation, Oriflame Global R&D. EdytaKurek, Senior VP & Head, Oriflame India and Indonesia, added that the innovation aligns with consumer demand for long-term, science-backed skincare solutions.
In Shillong, the premium skincare segment has witnessed a surge in interest following the Oripeptide-3 launch. Local outlets and Oriflame partner stores report increased footfall, particularly among young professionals and working women seeking advanced anti-ageing solutions. Retail analysts note that the brand’s presence is strengthening in the northeastern market, with consumer preference shifting toward evidence-based, longevity-focused skincare products.
Oriflame, operating in over 60 countries, continues to leverage research-driven innovation and sustainability to expand its market share in the high-growth global skincare sector.